Erasca, Inc.
ERAS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761918
No open-market purchases or sales by Erasca, Inc. insiders were filed in the last 90 days; 256 institutions reported holding it in 13F filings for Q2 2026, worth $5.13B in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Erasca, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 119 | 108 | −11 |
| Shares | 69.2M | 72.7M | +3.43M (+5.0%) |
| Value | $147.5M | $149.7M | +$2.20M (+1.5%) |
New holders (20)
Institutions that held Erasca, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sio Capital Management, LLC | 2,427,184 | $5.00M | 1.74% |
| CVI Holdings, LLC | 1,456,311 | $3.00M | 2.82% |
| Point72 Asset Management, L.P. | 1,096,254 | $2.26M | 0.01% |
| ExodusPoint Capital Management, LP | 249,518 | $514.0K | 0.01% |
| Silverarc Capital Management, LLC | 223,845 | $461.1K | 0.13% |
| IPG Investment Advisors LLC | 207,470 | $427.4K | 0.09% |
| AQR Capital Management LLC | 122,162 | $251.7K | 0.00% |
| Susquehanna Fundamental Investments, LLC | 104,691 | $215.7K | 0.01% |
| Palumbo Wealth Management LLC | 78,436 | $161.6K | 0.07% |
| Atom Investors LP | 50,533 | $104.1K | 0.01% |
| Prudential Financial Inc | 37,976 | $78.2K | 0.00% |
| Brevan Howard Capital Management LP | 18,638 | $38.4K | 0.00% |
| HSBC Holdings PLC | 15,619 | $32.2K | 0.00% |
| CI Private Wealth, LLC | 14,555 | $30.0K | 0.00% |
| Point72 Asia (Singapore) Pte. Ltd. | 9,565 | $19.7K | 0.01% |
| Point72 (DIFC) Ltd | 7,420 | $15.3K | 0.00% |
| Group One Trading, L.P. | 2,161 | $4.45K | 0.00% |
| Massmutual Trust Co FSB | 333 | $686 | 0.00% |
| Nisa Investment Advisors, LLC | 22 | $45 | 0.00% |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 18 | $37 | 0.00% |
Sold out (31)
Institutions that held Erasca, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.